A Comparative Prospective Study Between Conventional Chemo-Radiotherapy and Pure Accelerated Radiotherapy With Concurrent Chemotherapy for the Treatment of Locally Advanced Head and Neck Cancer
- PMID: 37602000
- PMCID: PMC10439807
- DOI: 10.7759/cureus.42206
A Comparative Prospective Study Between Conventional Chemo-Radiotherapy and Pure Accelerated Radiotherapy With Concurrent Chemotherapy for the Treatment of Locally Advanced Head and Neck Cancer
Abstract
Background: The established standard treatment for locally advanced head and neck squamous cell carcinoma is concurrent chemoradiotherapy, but the optimum radiotherapy schedule for best disease control and acceptable toxicity is still evolving. Tumor control probability decreases with each day's prolongation of treatment time. Shortening the overall treatment time of radiation by pure accelerated radiotherapy may be a good option.
Material and methods: One hundred and sixty-five patients with histopathologically proven squamous cell carcinoma of the head and neck were included in the study and were assigned into two groups from January 2017 to June 2019. The total dose of 70 Gy was given, 2 Gy/fraction/day. Treatment was given five days a week (conventional radiotherapy) and six days a week (pure accelerated radiotherapy). Both groups received weekly concurrent injections of cisplatin.
Results: The stage (p=0.006) and fractionation of radiation (p=0.018) were the independent factors affecting disease-free survival (DFS). There was a statistically significant difference (p=0.019) in the recurrence of patients in different fractionation schedules. The median DFS was 39 months with a 95% CI of 31.44 - 46.55. One- and three-year DFS was 51% and 8.5% respectively in the five fractions/week schedule arm while 54.5% and 9.5% respectively in the six fractions/week schedule group.
Conclusion: Pure accelerated radiotherapy is more efficacious in terms of disease control with comparable mildly increased acute side effects.
Keywords: acute side effects; conventional chemoradiotherapy; dfs; locally advanced head neck cancer; pure accelerated radiotherapy.
Copyright © 2023, Das et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures



References
-
- Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Grégoire V, Lefebvre JL, Licitra L, Felip E. Ann Oncol. 2010;21 Suppl 5:0–6. - PubMed
-
- Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Bourhis J, Overgaard J, Audry H, et al. Lancet. 2006;368:843–854. - PubMed
-
- A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Fu KK, Pajak TF, Trotti A, et al. Int J Radiat Oncol Biol Phys. 2000;48:7–16. - PubMed
-
- Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: Results of the EORTC 22851 randomized trial. Horiot JC, Bontemps P, van den Bogaert W, et al. Radiotherapy Oncol. 1997;44:111–121. - PubMed
-
- Five compared with six fractions per week of conventional radiotherapy of squamous cell carcinoma of head and neck: DAHANCA 6 and 7 randomized controlled trial. Overgaard J, Hansen HS, Specht L, et al. Lancet. 2003;362:933–940. - PubMed
LinkOut - more resources
Full Text Sources